Celgene NEWS
When Bristol-Myers Squibb picked up Celgene in one of biopharma's biggest deals ever last month, investors tagged one big risk: Celgene's megablockbuster ...
Celgene stock and Dr. Reddy's stock diverged Monday after U.S. officials declined to move forward with a patent challenge for cancer drug Revlimid.
Gilead stock has been stagnating, but there are other choices for investors. How about considering Celgene over GILD stock?
A hedge fund potentially agitating for blocking the acquisition by Bristol-Myers adds risk to the short-term story. A $2.2 billion breakup fee reduces the risk.
Both drugmakers have reported their Q4 results and provided guidance for 2019. And Celgene isn't just doing fine on its own: It's beating Bristol-Myers Squibb.
Celgene Corporation (NASDAQ:CELG) stock enjoyed an overall uptrend of 38.99% from the beginning of 2019. The closing share price quoted for February 12, ...
SAN FRANCISCO — Celgene is famous for cultivating a constellation of biotech partners — companies whose fortunes are poised to be shifted by last month's ...
Celgene Corporation CELG is likely to beat expectations when it reports fourth-quarter results on Jan 31, before the opening bell. In the last reported quarter, the ...
Celgene currently (01/15/2019) trades for $88.2 which signals uncertainty among investors. The fair value for the combined company and thus for Celgene's ...
O Dell Group LLC reduced its stake in shares of Celgene Co. (NASDAQ:CELG) by 5.7% during the 4th quarter, according to the company in its most recent 13F ...
Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher ...
Celgene earnings and sales topped expectations in the fourth quarter. The biotech also issued consensus-beating guidance. Celgene stock dipped a fraction.
Celgene stock (CELG) was higher Friday morning, rising $1.54 to $88 per share, after the CEO of AbbVie (ABBV) said on the company's earnings conference ...
Shares of Celgene Corporation CELG, +2.23% rose 0.4% in premarket trade Thursday after the company announced fourth-quarter earnings that beat profit and ...
Celgene Corporation (NASDAQ:CELG) recently had a high trading volume day. The volume for the company on 12-Feb-19 was recorded to be 8427339 ...
Celgene approached only one other pharmaceutical company about the possibility of a deal as it negotiated an acquisition by Bristol-Myers Squibb, ultimately ...
As Biotechnology businesses, Celgene Corporation (NASDAQ:CELG) and Wave Life Sciences Ltd. (NASDAQ:WVE), are affected by contrast. This especially ...
The drugmaker's fourth-quarter results were great. It's the prospects for future quarters that make the Celgene deal look appealing.
Celgene Corporation (NASDAQ:CELG) Q4 2018 Earnings Conference Call January 31, 2019 09:00 AM ET Company Participants Nina Goworek - Executive ...
Celgene ([[CELG]] -2.8%) is down on modestly higher volume in apparent to response to the potential involvement of activist investor Starboard Value via a.
Cobblestone Capital Advisors LLC NY cut its stake in shares of Celgene Co. (NASDAQ:CELG) by 7.5% during the fourth quarter, according to its most recent ...
Billionaire John Paulson sees a 10 percent to 20 percent chance that Bristol-Myers Squibb Co. receives a takeover bid and he's positioning his Celgene Corp.
Over the past 9 days, Celgene Corporation (NASDAQ: CELG) stock was observed to have a Historic Volatility of 20.05%. That figure, when expanded to look at ...
At the start of the year, Gilead Sciences (NASDAQ:GILD) and Celgene (NASDAQ:CELG) were arguably the biggest value plays in the biotech industry. Gilead ...
On Tuesday, Celgene Corporation (CELG) made the way into the market negative movers list with falling -0.88%. CELG reported a change of 1.07% over the ...
Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Celgene Co. (NASDAQ:CELG) by 19.7% in the fourth quarter, according to its most recent ...
The Bristol-Myers Squibb acquisition undervalues Celgene. Bristol-Myers would also be undervalued post-deal at current prices. I am inclined to keep the BMY ...
Newmont Mining Corporation (NYSE: NEM) experienced a high price of $33.81 with a low value of $33.28 at the end of the last trading session, which followed ...
Two local biotech startups working on potential cancer treatments said Friday that they have made deals to collaborate with Celgene, the New Jersey-based ...
The company disclosed this week that bought a boatload more of Acceleron Pharma stock. Celgene paid $30.4 million to buy 706206 more Acceleron shares on ...
Both Celgene Corporation (NASDAQ:CELG) and Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) are Biotechnology companies, competing one another.
CELG earnings call for the period ending December 31, 2018.
Celgene (CELG) delivered earnings and revenue surprises of 3.02% and 1.48%, respectively, for the quarter ended December 2018. Do the numbers hold clues ...
This week's Idea Guide breaks down our coverage of the Bristol-Myers/Celgene deal. Our contributors express a mix of investor fatigue, excitement about the ...
Atlas Venture-backed Kyn Therapeutics hopes to create drugs that reverse the effects of a metabolite called kynurenine, which cancer cells use to suppress the ...
Editor's Note: With Celgene showcasing its "continued commitment to work with partners" in twin deals today, we asked Chris Dokomajilar, founder and CEO of ...
Celgene (CELG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key ...
The shares of Celgene Corporation (NASDAQ:CELG) went up during the trading session by $1.96 on Monday, trading at $89.87. At the moment, the company ...
NEW YORK, Feb. 5, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and ...
Want to know why an industry that views itself as lifesaving and heroic is viewed by much of the public as price gouging and venal? Look here.
American Financial Group Inc increased its stake in Celgene Corp (CELG) by 100% based on its latest 2018Q3 regulatory filing with the SEC. American ...
Celgene (CELG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key ...
Celgene (NASDAQ:CELG) is scheduled to announce Q4 earnings results on Thursday, January 31st, before market open. The consensus EPS Estimate is $2.32 ...
Celgene and Kyn Therapeutics enter a licensing agreement to develop Kyn's immuno-oncology pipeline for investigative therapies after Celgene was acquired ...
Investors making a wish list of stocks to watch should take a look at Celgene Corporation (NASDAQ:CELG). The stock is offering a price-to-sales ratio of 4.02.
Despite a looming takeover by BMS, Celgene hasn't stopped making deals. It's just added two more partnerships for cancer immunotherapies.
As the dust settles on Bristol-Myers Squibb's takeout of Celgene it is not just big pharma that is left wondering where it now stands. A slew of smaller companies ...
First Interstate Bank decreased its stake in Celgene Corp (CELG) by 80.76% based on its latest 2018Q3 regulatory filing with the SEC. First Interstate Bank Smith ...
SUMMIT, N.J.--(BUSINESS WIRE)--Jan 31, 2019--Celgene Corporation (NASDAQ: CELG) reported operating results for the fourth quarter and full year of 2018.
U.S. Representatives Peter Welch and Francis Rooney are urging the Federal Trade Commission and Department of Justice to take a close look at ...
Oaktop Capital Management Ii Lp increased its stake in Celgene Corp Com (CELG) by 0.53% based on its latest 2018Q3 regulatory filing with the SEC. Oaktop ...
Wall Street analysts have the ability to provide stock ratings for companies that they track. Based on analysts used by Zacks Research, the present average.
The stock of The Procter & Gamble Company (NYSE:PG) witnessed a 40.34% increase from the 52-week low price of $70.73. Their shares price went up by ...
Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).
LOUGHLIN JAMES J, Director, sold 23,466 shares of the Celgene Corporation (NASDAQ:CELG) in an exchange that happened on February 7th. The stock was ...
Dudley & Shanley Llc increased its stake in Adamas Pharma Inc. (ADMS) by 135.24% based on its latest 2018Q3 regulatory filing with the SEC. Dudley ...
Celgene Corp (CELG) are under the spotlight as the Chikou span line has crossed above the Tenkan line. The Ichimoku signals, indeed all Ichimoku.
First Long Island Investors Llc increased its stake in Celgene Corp Com (CELG) by 10.82% based on its latest 2018Q3 regulatory filing with the SEC. First Long ...
Taylor Asset Management Inc increased its stake in Celgene Corp (CELG) by 11.35% based on its latest 2018Q3 regulatory filing with the SEC. Taylor Asset ...
For Immediate Release. Chicago, IL - February 12 2018 - Zacks Equity Research Take-Two Interactive Software, Inc. TTWO as the Bull of the Day, Las Vegas ...
The Earnings to Price yield of Celgene Corporation (NasdaqGS:CELG) is 0.045955. This is calculated by taking the earnings per share and dividing it by the.
The share price of Celgene Corporation (NASDAQ: CELG) has taken quite a journey since the beginning of the year, with a year-to-date change of +25.78.
On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an R&D (research and development) expense-to-sales ratio of 15.5% and an SG&A ...
Cls Investments Llc increased its stake in Celgene Corp (CELG) by 6033.26% based on its latest 2018Q3 regulatory filing with the SEC. Cls Investments Llc ...
Davidson D A & Company decreased its stake in Celgene Corp (CELG) by 40.84% based on its latest 2018Q3 regulatory filing with the SEC. Davidson D A ...
The House Oversight and Government Reform Committee has asked several pharmaceutical companies to explain why the costs of life-saving drugs keep going ...
Celgene Corporation (NASDAQ:CELG) and Clearside Biomedical Inc. (NASDAQ:CLSD) are two firms in the Biotechnology that compete against each other.
On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.
C-suite moves at cancer biotech Geron Corp, EMD Serono Inc and Kiadis Pharma, while German biotech MorphoSys AG names David Trexler as its new ...
State Of New Jersey Common Pension Fund D increased its stake in Celgene Corp (CELG) by 10.67% based on its latest 2018Q3 regulatory filing with the SEC.
Expected Earnings Release: 01/31/2019, PremarketAvg. Extended-Hours Dollar Volume: $30712829Celgene Corporation ( CELG ) is due to issue its.
After a recent check, we have noticed that the Chaikin Oscillator is above zero for Celgene Corp (CELG). Traders may be paying close attention to the stock and.
In this episode of "The Readout LOUD," we pick apart the surprising news that the CEO of CRISPR-focused Editas Medicine is quitting her job come March.
Archford Capital Strategies Llc increased its stake in Microchip Technology Inc Com (MCHP) by 9065% based on its latest 2018Q3 regulatory filing with the SEC ...
Aleksandra Rizo has been appointed chief medical officer of Geron (NASDAQ: ]). Rizo comes to the Menlo Park, CA, drug developer from Summit, NJ-based.
Shelton Capital Management lessened its stake in Celgene Co. (NASDAQ:CELG) by 6.6% during the fourth quarter, HoldingsChannel.com reports. The firm ...
Celgene (NASDAQ:CELG) updated its FY 2019 earnings guidance on Thursday. The company provided EPS guidance of $10.60-10.80 for the period, ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 30) ...
Bristol-Myers Squibb is buying cancer drugmaker Celgene in a cash and stock deal valued at $74 billion, the companies announced Thursday. Under the ...
On the same day Celgene Corp. was announcing that it would be acquired by Bristol-Myers Squibb Co. in the biggest pharma deal ever, the company was also ...
Yesterday, Bristol-Myers Squibb announced a deal to acquire Celgene. This was biggest deal in the biotech sector in many, many years. While Celgene has ...
Celgene had some bad news, driving the stock to bargain prices in 2018. Ozanimod and Fedratinib applications to the FDA will be good signs. Multiple sales ...
Celgene Corporation (NASDAQ:CELG) has been one of the worst-performing big biotech stocks of the past year even though the company has consistently ...
Risks? Celgene has plenty of them. But the big biotech also looks like a bargain with tremendous growth prospects.
The biotech's shares look too cheap to Jefferies analyst Michael Yee, and he compares Celgene to Gilead in 2009.
Celgene (NASDAQ:CELG) is a global biopharmaceuticals company, which has recently entered into a merger agreement with Bristol-Myers Squibb in a deal ...
Celgene increased 2018 revenue expectations for the second time this year as strong growth continues. Celgene's rock-bottom Forward P/E of 6.59x and PEG ...
Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.
Investors are looking forward to Revlimid's performance and other pipeline updates when Celgene (CELG) reports Q3 results on Oct 25.
Analysts expect Celgene Co. (NASDAQ:CELG) to announce earnings per share (EPS) of $2.32 for the current quarter, Zacks reports. Seven analysts have ...
Which big biotech is the better stock pick at the moment?
CELG is a lot cheaper than this time last year. I look at the threat to Revlimid from generics manufacturers. I comment on the ongoing ozanimod story.
Two drug stocks diverged in a yellow wood. And sorry I could not buy both and be one investor, long I stood. My apologies to Robert Frost for butchering his ...
Celgene (NASDAQ:CELG) continues to post solid revenue gains from its current drugs, but with generics of top-selling Revlimid slated to hit the market starting ...
Celgene announces positive preliminary data from its study treating patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic ...
Both of these drugmaker stocks have stumbled recently, but which is the better stock right now?
Celgene dipped to multi-year lows of $70. The major culprit was biotech sector weakness causing money to flow away. The net payout yield has surged to 17%, ...
Celgene Corp. (NASDAQ:CELG) is one of biotech's largest companies, but that hasn't kept shares from falling in the past year because of disappointments and ...
Celgene is traded at multi-year lows due to upcoming Revlimid loss of exclusivity in 2022. Celgene argues that upcoming new agents will substitute Revlimid ...
Celgene Corporation (NASDAQ:CELG) Credit Suisse 27th Annual Healthcare Conference Call November 14, 2018 10:45 AM ET Executives Terrie Curran ...
Celgene Videos
Bristol-Myers and Celgene CEOs talk acquisition deal
Bristol-Myers, Celgene deal in focus
Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene
Celgene deal is a 'bold' move: Fmr. Medtronic CEO
Jefferies: Buy Celgene, lowest P/E in history
Bristol-Myers' Celgene acquisition is the start of pharmaceutical industry mergers: analyst
Celgene Stock - Is Celgene Stock a Buy Today?
This is a good deal for Celgene: Bernstein analyst
Celgene Corporation (CELG) Stock Analysis 2018
Why Did the Stock Market Shun Bristol-Myers $74B Deal for Celgene?
Celgene Images
![[VIDEO] La Défense : KPMG dévoile ses nouveaux espaces de ...](/url/?u=http://media.springernature.com/full/springer-static/image/art:10.1186/s13148-016-0264-8/MediaObjects/13148_2016_264_Fig3_HTML.gif)
